Similar articles for PMID: 19787792

Year	Number of Results
1995	2
1996	3
1997	1
1998	3
1999	2
2000	1
2001	2
2003	2
2005	2
2006	5
2007	1
2008	2
2009	4
2010	1
2011	1
2016	1
2019	1
2024	0

1

Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort.

Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U, Mackintosh C, de Alava E, Myklebost O, Kresse SH, Meza-Zepeda LA, Serra M, Cleton-Jansen AM, Hogendoorn PC, Buerger H, Aigner T, Gabbert HE, Poremba C. Ottaviano L, et al. Genes Chromosomes Cancer. 2010 Jan;49(1):40-51. doi: 10.1002/gcc.20717. Genes Chromosomes Cancer. 2010. PMID: 19787792

2

TabBO: a model reflecting common molecular features of androgen-independent prostate cancer.

Navone NM, Rodriquez-Vargas MC, Benedict WF, Troncoso P, McDonnell TJ, Zhou JH, Luthra R, Logothetis CJ. Navone NM, et al. Clin Cancer Res. 2000 Mar;6(3):1190-7. Clin Cancer Res. 2000. PMID: 10741751

3

Unique substitution of CHEK2 and TP53 mutations implicated in primary prostate tumors and cancer cell lines.

Zheng L, Wang F, Qian C, Neumann RM, Cheville JC, Tindall DJ, Liu W. Zheng L, et al. Hum Mutat. 2006 Oct;27(10):1062-3. doi: 10.1002/humu.9457. Hum Mutat. 2006. PMID: 16941491

4

Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer.

Markl ID, Jones PA. Markl ID, et al. Cancer Res. 1998 Dec 1;58(23):5348-53. Cancer Res. 1998. PMID: 9850064

5

Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.

Worsham MJ, Chen KM, Tiwari N, Pals G, Schouten JP, Sethi S, Benninger MS. Worsham MJ, et al. Arch Otolaryngol Head Neck Surg. 2006 Apr;132(4):409-15. doi: 10.1001/archotol.132.4.409. Arch Otolaryngol Head Neck Surg. 2006. PMID: 16618910

6

Detailed computational study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants.

Greenblatt MS, Beaudet JG, Gump JR, Godin KS, Trombley L, Koh J, Bond JP. Greenblatt MS, et al. Oncogene. 2003 Feb 27;22(8):1150-63. doi: 10.1038/sj.onc.1206101. Oncogene. 2003. PMID: 12606942

7

Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations.

Havrilesky LJ, Alvarez AA, Whitaker RS, Marks JR, Berchuck A. Havrilesky LJ, et al. Gynecol Oncol. 2001 Dec;83(3):491-500. doi: 10.1006/gyno.2001.6464. Gynecol Oncol. 2001. PMID: 11733961

8

Role of p16/MTS1, cyclin D1 and RB in primary oral cancer and oral cancer cell lines.

Sartor M, Steingrimsdottir H, Elamin F, Gäken J, Warnakulasuriya S, Partridge M, Thakker N, Johnson NW, Tavassoli M. Sartor M, et al. Br J Cancer. 1999 Apr;80(1-2):79-86. doi: 10.1038/sj.bjc.6690505. Br J Cancer. 1999. PMID: 10389982 Free PMC article.

9

CDKN2A/p16 is inactivated in most melanoma cell lines.

Castellano M, Pollock PM, Walters MK, Sparrow LE, Down LM, Gabrielli BG, Parsons PG, Hayward NK. Castellano M, et al. Cancer Res. 1997 Nov 1;57(21):4868-75. Cancer Res. 1997. PMID: 9354451

10

Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression.

Geradts J, Kratzke RA, Niehans GA, Lincoln CE. Geradts J, et al. Cancer Res. 1995 Dec 15;55(24):6006-11. Cancer Res. 1995. PMID: 8521382

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

32 results

Results by year